With millions of people suffering from chronic back pain, Discure Technologies Ltd. is hoping that its bioelectronic therapy, the Discure system, will soon bring relief.

Basel Medical Group Ltd. is the first Singapore-based med-tech to price an IPO on the Nasdaq this year, aggregating gross proceeds of $8.82 million on its debut. The funds will be used to power future M&As and business expansion plans in Singapore and Southeast Asia, the company said.

Basel Medical Group Ltd. is the first Singapore-based med-tech to price an IPO on the Nasdaq this year, aggregating gross proceeds of $8.82 million on its debut. The funds will be used to power future M&As and business expansion plans in Singapore and Southeast Asia, the company said.

The U.S. Preventive Services Task Force updated a 2018 series of recommendations for screening for osteoporosis, but the update has its detractors.

Reev SAS raised $9.2 million in a financing round that will fund further development of its lightweight exoskeleton Dreeven.

Cornerstone Robotics Ltd. raised more than $70 million in a series C round to expand its international footprint and accelerate R&D efforts for its robotic surgery solutions. The funds will allow the Hong Kong-headquartered company to accelerate commercialization of new surgical robotic products, conduct clinical trials, obtain regulatory approvals and promote global adoption of advanced robotic surgical solutions.

After raising AU$7 million (US$4.5 million) in is initial public offering on the Australian Securities Exchange last week, Renerve Ltd. is already exploring mainland China for its portfolio of nerve repair and regeneration products.

Korean med-tech firm Innosys Co. Ltd. recently launched two new injectable spine bone graft substitute products – Velofuse Gel and Velofuse Putty – and announced a name change to CG Medtech Co. Ltd., effective Nov. 4, 2024.

Neo Medical SA raised $68 million in a series B financing round to accelerate the growth of its spine surgical technologies in the U.S. The infusion of funds allows the company to deploy new products and enhance its artificial intelligence-driven augmented reality platform.

Avicenna.ai SAS received U.S. FDA clearance for its Cina-Cspine algorithm, which uses machine learning technology to detect and triage cervical spine fractures from computed tomography images. The tool automatically flags imaging findings that are compatible with acute cervical spine fractures, which can cause serious neurological damage or paralysis.